M1413 Pos pdl1 bef initial ici treatment
Also known as: PD-L1 positive status, tumor PD-L1 expression, pos pdl1 bef init ici
Performance measure documenting positive Programmed Death-Ligand 1 (PD-L1) expression before initiation of immunotherapy in metastatic non-small cell lung cancer.
In Plain Language
Tumor protein marker for immunotherapy response; Cancer cell immune protein expression positive
Clinical Context
Documents PD-L1 tumor expression status before immunotherapy initiation. Critical for first-line immunotherapy patient selection in NSCLC.
RVU Information
CPT M1413 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M1413?
CPT M1413 (Pos pdl1 bef initial ici treatment) is a M Codes code. Performance measure documenting positive Programmed Death-Ligand 1 (PD-L1) expression before initiation of immunotherapy in metastatic non-small cell lung cancer.
Is M1413 covered by insurance?
M1413 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Documents PD-L1 tumor expression status before immunotherapy initiation. Critical for first-line immunotherapy patient selection in NSCLC.
When is CPT M1413 used?
Documents PD-L1 tumor expression status before immunotherapy initiation. Critical for first-line immunotherapy patient selection in NSCLC.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.